These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 577507)

  • 21. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.
    Vogt D; Trenk D; Bonn R; Jähnchen E
    Eur J Clin Pharmacol; 1994; 46(4):319-24. PubMed ID: 7957516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of nitrates.
    Bogaert MG
    Cardiovasc Drugs Ther; 1994 Oct; 8(5):693-9. PubMed ID: 7873466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
    Fung HL
    Am Heart J; 1985 Jul; 110(1 Pt 2):213-6. PubMed ID: 4013997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
    Bonn R
    Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers.
    Sawicki W; Deptulski T; Janicki S
    Pharmazie; 1989 Apr; 44(4):280-1. PubMed ID: 2772003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms].
    Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G
    Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
    Thomson AH; Miller SH; Green ST; Whiting B
    Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.
    Morrison RA; Wiegand UW; Jähnchen E; Höhmann D; Bechtold H; Meinertz T; Fung HL
    Clin Pharmacol Ther; 1983 Jun; 33(6):747-56. PubMed ID: 6851405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy.
    Thadani U; Fung HL; Darke AC; Parker JO
    Am J Cardiol; 1982 Feb; 49(2):411-9. PubMed ID: 7058754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations].
    Chasseaud LF; Taylor T; Major RM; Taylor IW; Luckow V; Darragh A; Lambe RF
    Arzneimittelforschung; 1983; 33(9):1298-301. PubMed ID: 6685511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations.
    Galeazzi RL; Platzer R; Reutemann G
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):387-93. PubMed ID: 6629543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single administration of atenolol does not influence the kinetics of orally given isosorbide dinitrate.
    Bogaert MG; Rosseel MT; Bruyneel K
    Int J Clin Pharmacol Res; 1983; 3(6):491-3. PubMed ID: 6678835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet.
    Kosoglou T; Kazierad DJ; Schentag JJ; Patrick JE; Heimark L; Radwanski E; Christopher D; Flannery BE; Affrime MB
    J Clin Pharmacol; 1995 Feb; 35(2):151-8. PubMed ID: 7751425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.